BiotechTube

Docetaxel + TroVax

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Refractory Prostate Cancer

Conditions

Hormone Refractory Prostate Cancer

Trial Timeline

Aug 1, 2010 → Mar 1, 2013

NCT ID
NCT01194960

About Docetaxel + TroVax

Docetaxel + TroVax is a phase 2 stage product being developed by Oxford Biomedica for Hormone Refractory Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01194960. Target conditions include Hormone Refractory Prostate Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Hormone Refractory Prostate Cancer were approved

Approved (9) Terminated (2) Active (11)
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
✅Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Saizen + SaizenMerckApproved
✅Zoledronic Acid + PlaceboNovartisApproved
✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01194960Phase 2Terminated

Competing Products

20 competing products in Hormone Refractory Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
44
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
YM598Astellas PharmaPhase 2
27
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropinSun PharmaceuticalPhase 3
40
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
35
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
50
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29